Chimmitecan is a potent topisomerase I inhibitor. Chimmitecan is also an active metabolite of simmitecan. Chimmitecan exhibits outstanding activity in vitro and in vivo. The substitution at the 9-position benefits chimmitecan a salient anti-MDR activity, stability in human serum albumin, improved solubility, and orally bioavailable availability, which might favorably promise its therapeutic potential in clinical settings. References: Hu Z, Sun Y, Du F, Niu W, Xu F, Huang Y, Li C. Accurate determination of the anticancer prodrug simmitecan and its active metabolite chimmitecan in various plasma samples based on immediate deactivation of blood carboxylesterases. J Chromatogr A. 2011 Sep 23;1218(38):6646-53. doi: 10.1016/j.chroma.2011.07.042. Epub 2011 Jul 23. PubMed PMID: 21839460.

纯度：≥98%

CAS：185425-25-6